Effects of medicated diet to eradicate Helicobacter spp. on growth, pathology, and infection status in Rag1-/- and nude mice.
The use of a commercial 4-drug diet has been shown to eradicate Helicobacter spp. from immunocompetent mice and those with innate immunodeficiencies. However the efficacy of this diet has not been confirmed in mice with altered adaptive immunity. We hypothesized that an 8-wk treatment with medicated diet would eradicate H. hepaticus and H. typhlonius from young naturally infected nude and Rag1 mice lacking functional T cells (Foxn1(nu)) or T and B cells (B6.129S7-Rag1(tm1Mom)/J), respectively. We evaluated helicobacter status, body weight, and gross and histologic changes between medicated and control diet in groups of infected and uninfected mice throughout treatment and at 8 wk after treatment completion. Initial infection status was confirmed by fecal PCR at weaning and 3 wk later, with study initiation in 7-wk-old mice. PCR testing demonstrated that independent of strain and sex, all treated mice tested negative for Helicobacter spp. after 4 wk of treatment and remained negative for the duration of the study. Irrespective of infection status, nude and Rag1 mice fed 8 wk of medicated diet gained less weight than did their untreated controls. Both strains normalized body weight while on control diet for the 8 wk after treatment. Mice fed medicated diet developed severe gastroesophageal hyperkeratosis, suggestive of reduced feed consumption, and enlarged ceca. These conditions improved or resolved after the return to control diet. This report is the first to demonstrate the efficacy and physical effects of providing medicated diet for the eradication of Helicobacter spp. from mice with adaptive immune deficiencies.
Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. cgarre12@jhmi.edu.
Caroline M
CM
Garrett
Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Dillon
D
Muth
Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Julie
J
Watson
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D001835:Body Weight; D002432:Cecum / Q000473:pathology; D004032:Diet; D005243:Feces / Q000382:microbiology; D016998:Helicobacter / Q000145:classification / Q000502:physiology*; D016481:Helicobacter Infections / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology / Q000662:veterinary*; D018398:Homeodomain Proteins / Q000235:genetics; D016867:Immunocompromised Host; D051379:Mice; D008810:Mice, Inbred C57BL; D008819:Mice, Nude; D016513:Mice, SCID; D016133:Polymerase Chain Reaction; D011897:Random Allocation; D012376:Rodent Diseases / Q000188:drug therapy* / Q000276:immunology* / Q000382:microbiology
D000900:Anti-Bacterial Agents; D018398:Homeodomain Proteins; C064658:RAG-1 protein